Latest News
Manuscript demonstrating Laminin-111 effectively treats a mouse model of MDC1A is accepted for publication in the American Journal of Pathology
Laminin-111 is granted Orphan Drug status for the treatment of Congenital Muscular Dystrophy Type 1A (MDC1A)
Laminin-111 is granted Orphan Drug status for the treatment of Duchenne Muscular Dystrophy (DMD)
Struggle Against Muscular Dystrophy (SAM) donates $100,000 to Prothelia to support the development of Prothelia's lead therapeutic, Laminin-111
Prothelia is developing therapies for three forms of muscular dystrophy
Duchenne muscular dystrophy (DMD)
Congenital muscular dystrophy type 1A (MDC1A)
Dystroglycanopathy (LGMD2I)
Laminin-111 and PRT-300, if approved, will treat ALL patients with DMD, MDC1A and LGMD2I regardless of their respective mutations and complement the effectiveness of other therapies in development for DMD such as utrophin enhancement, exon skipping or biglycan.
Pipeline |
Class |
Discovery |
Optimization |
Preclinical |
Phase 1/2/3 |
Indication |
Partner |
PRT-01 (Laminin-111) |
Protein |
MDC1A, DMD LGMD2I |
Open |
||||
PRT-300 |
Small Molecule |
MDC1A, DMD LGMD2I |
Open |
||||
PRT-400 |
Protein |
DMD |
|||||
PRT-500 |
Protein |
DMD |
